1. Phylogeny  
   Cyclin‐dependent kinase 7 (CDK7), alternatively known as CAK1, MO15, or STK1, is a member of the cyclin‐dependent kinase (CDK) family that is evolutionarily conserved across eukaryotes. In metazoans, CDK7 functions as the principal CDK‐activating kinase (CAK) and is integrated into transcriptional control as well as cell cycle regulation. Orthologs of CDK7 have been identified from yeast to mammals, although yeast employs a distinct CAK (Cak1/Civ1) that is functionally divergent from the metazoan CDK7, underscoring an evolutionary separation in the regulation of transcriptional versus cell‐cycle CDKs (fisher2019cdk7akinase pages 1-3, liu2000evolutionofcyclindependent pages 1-2). CDK7 clusters phylogenetically with other transcription‐regulating CDKs within the CMGC kinase group, a clade that includes CDKs such as CDK8 and CDK9 that are predominantly involved in transcription. Its close association with components of the general transcription factor TFIIH as well as its role in activating cell cycle kinases situates it within a central evolutionary core of eukaryotic signaling pathways that emerged early in eukaryotic evolution (malumbres2014cyclindependentkinases pages 1-2, galbraith2019therapeutictargetingof pages 1-3). In light of these relationships, CDK7 is considered part of the core set of kinases that have been preserved from the Last Eukaryotic Common Ancestor (LECA) and remain indispensable for both cell cycle progression and transcription regulation (fisher2019cdk7akinase pages 1-3).
2. Reaction Catalyzed  
   CDK7 catalyzes the transfer of a phosphate group from ATP to the hydroxyl group of serine/threonine residues on its protein substrates. The general reaction can be written as:  
     ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺  
   This phosphorylation reaction is central to its dual role in executing transcription initiation via the phosphorylation of the carboxy-terminal domain (CTD) of RNA polymerase II and in activating other cyclin-dependent kinases through phosphorylation of a conserved threonine in their activation (T) loops (fisher2019cdk7akinase pages 1-3, lolli2005cak—cyclindependentactivatingkinase pages 1-2).
3. Cofactor Requirements  
   The catalytic activity of CDK7 depends on the availability of adenosine triphosphate (ATP) as the phosphate donor and requires divalent metal ions, typically magnesium (Mg²⁺), to facilitate the proper binding of ATP to its active site. This cofactor requirement is essential for the enzyme’s serine/threonine kinase activity, as Mg²⁺ coordinates with the phosphate groups of ATP to stabilize the transition state during the phosphoryl transfer reaction (gallorini2012cyclindependentkinasemodulators pages 3-5).
4. Substrate Specificity  
   CDK7 exhibits a distinct substrate specificity that reflects its dual function as both a CDK-activating kinase (CAK) and a regulator of transcription. Regarding its role in cellular activation of other CDKs, CDK7 phosphorylates a conserved threonine residue in the activation loop of target kinases such as CDK1, CDK2, CDK4, and CDK6, which is critical for their catalytic activity. In its transcriptional role, CDK7 phosphorylates the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II (POLR2A) at serine residues—predominantly Ser5 and Ser7—within its heptad repeat sequence (Y₁S₂P₃T₄S₅P₆S₇). The consensus substrate motif for transcriptional phosphorylation does not entirely follow the classical proline-directed signature observed for many serine/threonine kinases but is defined by the repeated heptad structure unique to RNA polymerase II (galbraith2019therapeutictargetingof pages 6-7, fisher2019cdk7akinase pages 1-3). Additionally, CDK7 phosphorylates other substrates implicated in transcription and RNA processing such as the elongation factor SPT5, splicing factor SF1, and the tumor suppressor p53, thereby expanding its substrate repertoire beyond core CDKs and the RNA polymerase II CTD (fisher2019cdk7akinase pages 1-3, lolli2005cak—cyclindependentactivatingkinase pages 2-3).
5. Structure  
   CDK7 possesses a canonical serine/threonine kinase fold composed of two lobes: an N-terminal lobe primarily composed of β-sheets and a larger C-terminal lobe that is predominantly α-helical. The interface between these lobes forms the ATP-binding cleft where catalysis occurs. A key structural feature is the PSTAIRE helix, common to many CDKs, which undergoes repositioning upon cyclin binding to facilitate substrate access. CDK7 forms a heterotrimeric complex with cyclin H and MAT1; this association is essential for its full catalytic activity and substrate specificity. The cyclin H subunit plays a critical role in inducing the required conformational changes in CDK7, while MAT1 serves as a scaffolding protein that stabilizes the CAK complex and facilitates its integration into the transcription factor TFIIH (fisher2019cdk7akinase pages 1-3, malumbres2014cyclindependentkinases pages 5-6). Moreover, the active site of CDK7 features a unique cysteine residue (Cys312) within its ATP-binding pocket that is exploited by covalent inhibitors such as THZ1, providing a structural basis for its selective inhibition (galbraith2019therapeutictargetingof pages 6-7, lolli2005cak—cyclindependentactivatingkinase pages 4-5). These structural attributes, including the activation loop, the hydrophobic spine, and the position of the C-helix, are critical for the regulation of its kinase activity and its interaction with substrates and regulatory proteins.
6. Regulation  
   CDK7’s regulation is primarily achieved through post-translational modifications and its obligate association with cyclin H and MAT1. Phosphorylation of the T-loop (activation loop) of CDK7 is an essential modification that enhances its catalytic efficiency. Although CDK7 is often described as constitutively active during the cell cycle, its activity can be modulated by interaction with other proteins and by feedback mechanisms. For example, upon DNA damage, CDK7 phosphorylates p53, leading to the activation of cellular stress responses; in turn, activated p53 has been shown to inhibit CDK7 activity, establishing a regulatory feedback loop that can lead to cell cycle arrest and transcription inhibition (fisher2019cdk7akinase pages 1-3, lolli2005cak—cyclindependentactivatingkinase pages 2-3, malumbres2011physiologicalrelevanceof pages 4-6). Additionally, association with the general transcription factor TFIIH not only directs CDK7 substrate specificity towards the RNA polymerase II CTD but also contributes to its regulation through conformational constraints imposed by the multi-subunit complex (galbraith2019therapeutictargetingof pages 6-7, wohlbold2006thecyclindependentkinase pages 7-8). Inhibitory phosphorylation events and interactions with cyclin-dependent kinase inhibitors (CKIs) further modulate CDK7’s activity, ensuring that its kinase functions are tightly coupled to cell cycle progression and transcriptional control.
7. Function  
   CDK7 fulfills essential biological roles in both cell cycle progression and transcription. As the catalytic subunit of the CDK-activating kinase (CAK) complex, CDK7 phosphorylates and thereby activates several critical CDKs that govern transitions during the cell cycle. Notably, it activates the CDK1/cyclin B complex required for the G2–M transition and the CDK2/cyclin complexes that are pivotal for the G1–S transition. This activation is achieved via phosphorylation of a specific threonine residue in the T-loop of these kinases, which is necessary for their full catalytic activity (lolli2005cak—cyclindependentactivatingkinase pages 1-2, malumbres2005mammaliancyclindependentkinases pages 6-7).  
   In its transcriptional role, CDK7 is a component of the transcription factor IIH (TFIIH) complex; it phosphorylates the carboxy-terminal domain (CTD) of RNA polymerase II at Ser5 and Ser7 within the conserved heptad repeats. This phosphorylation event is critical for promoter clearance, the recruitment of capping enzymes, and the transition from transcription initiation to productive elongation. Thus, CDK7 links the regulation of gene expression to the control of the cell cycle, coordinating the activation of transcription with cell proliferation signals (fisher2019cdk7akinase pages 1-3, galbraith2019therapeutictargetingof pages 6-7).  
   Beyond these roles, CDK7 phosphorylates several ancillary substrates, including the elongation factor SPT5, the splicing factor SF1, and the tumor suppressor p53. Phosphorylation of these proteins contributes to the regulation of mRNA processing, the DNA damage response, and cellular growth inhibition. These interactions underscore the centrality of CDK7 in integrating cell cycle cues with the complex network of transcription regulation, ensuring precise control over cell proliferation and genome stability (fisher2019cdk7akinase pages 1-3, lolli2005cak—cyclindependentactivatingkinase pages 2-3).
8. Other Comments  
   Several small-molecule inhibitors have been developed that target CDK7 due to its pivotal role in oncogenic transcription and cell cycle control. Among these, covalent inhibitors such as THZ1 have shown selectivity by engaging a unique cysteine residue (Cys312) in the ATP-binding site of CDK7. These inhibitors have demonstrated potent anticancer activity in preclinical models by reducing RNA polymerase II-mediated transcription in cancer cells that exhibit transcriptional addiction. Furthermore, additional compounds such as SY-1365 have been advanced into clinical trials, emphasizing the therapeutic potential of targeting CDK7 (fisher2019cdk7akinase pages 7-8, galbraith2019therapeutictargetingof pages 6-7).  
   CDK7 is also associated with disease states; its overexpression or aberrant activity has been observed in various cancers, where it contributes to uncontrolled cell proliferation and deregulated transcription. In addition, since CDK7 phosphorylates p53 and other substrates involved in the DNA damage response, alterations in its regulation have implications for genome stability and apoptosis. The dual role of CDK7 in both activating cell cycle CDKs and promoting RNA polymerase II function has made it an attractive target for therapeutic intervention in cancer, where inhibitors may simultaneously disrupt critical cell cycle and transcriptional programs (malumbres2011physiologicalrelevanceof pages 4-6, wohlbold2006thecyclindependentkinase pages 7-8).
9. References
10. fisher2019cdk7akinase pages 1-3
11. galbraith2019therapeutictargetingof pages 1-3
12. galbraith2019therapeutictargetingof pages 5-6
13. galbraith2019therapeutictargetingof pages 6-7
14. gallorini2012cyclindependentkinasemodulators pages 3-5
15. lolli2005cak—cyclindependentactivatingkinase pages 1-2
16. lolli2005cak—cyclindependentactivatingkinase pages 2-3
17. lolli2005cak—cyclindependentactivatingkinase pages 3-4
18. lolli2005cak—cyclindependentactivatingkinase pages 4-5
19. malumbres2011physiologicalrelevanceof pages 4-6
20. malumbres2014cyclindependentkinases pages 1-2
21. malumbres2014cyclindependentkinases pages 2-3
22. malumbres2014cyclindependentkinases pages 5-6
23. malumbres2014cyclindependentkinases pages 6-7
24. umeda2005controlofcell pages 2-3
25. wohlbold2006thecyclindependentkinase pages 7-8
26. łukasik2021cyclindependentkinases(cdk) pages 23-25
27. łukasik2021cyclindependentkinases(cdk) pages 4-5
28. ding2020therolesof pages 21-23
29. ding2020therolesof pages 5-7
30. echalier2010recentdevelopmentsin pages 7-8
31. echalier2010recentdevelopmentsin pages 8-9
32. fisher2019cdk7akinase pages 7-8
33. gallorini2012cyclindependentkinasemodulators pages 2-3
34. harper2001cyclindependentkinases pages 2-4
35. liu2000evolutionofcyclindependent pages 1-1
36. liu2000evolutionofcyclindependent pages 1-2
37. liu2000evolutionofcyclindependent pages 2-3
38. malumbres2005mammaliancyclindependentkinases pages 3-3
39. malumbres2005mammaliancyclindependentkinases pages 6-7
40. schmitz2016cyclindependentkinasesas pages 1-2
41. umeda2005controlofcell pages 1-2
42. wohlbold2006thecyclindependentkinase pages 9-9
43. łukasik2021cyclindependentkinases(cdk) pages 1-2
44. łukasik2021cyclindependentkinases(cdk) pages 2-4
45. łukasik2021cyclindependentkinases(cdk) pages 21-22
46. suryadinata2010controlofcell pages 9-10
47. zheng2022cyclindependentkinasesand pages 10-12
48. zheng2022cyclindependentkinasesand pages 8-9
49. echalier2010recentdevelopmentsin pages 1-2
50. errico2010identificationofsubstrates pages 1-3

References

1. (fisher2019cdk7akinase pages 1-3): Robert P. Fisher. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription, 10:47-56, Dec 2019. URL: https://doi.org/10.1080/21541264.2018.1553483, doi:10.1080/21541264.2018.1553483. This article has 132 citations and is from a peer-reviewed journal.
2. (galbraith2019therapeutictargetingof pages 5-6): Matthew D. Galbraith, Heather Bender, and Joaquín M. Espinosa. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription, 10:118-136, Nov 2019. URL: https://doi.org/10.1080/21541264.2018.1539615, doi:10.1080/21541264.2018.1539615. This article has 96 citations and is from a peer-reviewed journal.
3. (galbraith2019therapeutictargetingof pages 6-7): Matthew D. Galbraith, Heather Bender, and Joaquín M. Espinosa. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription, 10:118-136, Nov 2019. URL: https://doi.org/10.1080/21541264.2018.1539615, doi:10.1080/21541264.2018.1539615. This article has 96 citations and is from a peer-reviewed journal.
4. (gallorini2012cyclindependentkinasemodulators pages 3-5): Marialucia Gallorini, Amelia Cataldi, and Viviana di Giacomo. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs, 26:377-391, Dec 2012. URL: https://doi.org/10.1007/bf03261895, doi:10.1007/bf03261895. This article has 94 citations and is from a peer-reviewed journal.
5. (lolli2005cak—cyclindependentactivatingkinase pages 1-2): Graziano Lolli and Louise N. Johnson. Cak—cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle, 4:565-570, Jan 2005. URL: https://doi.org/10.4161/cc.4.4.1607, doi:10.4161/cc.4.4.1607. This article has 309 citations and is from a peer-reviewed journal.
6. (lolli2005cak—cyclindependentactivatingkinase pages 2-3): Graziano Lolli and Louise N. Johnson. Cak—cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle, 4:565-570, Jan 2005. URL: https://doi.org/10.4161/cc.4.4.1607, doi:10.4161/cc.4.4.1607. This article has 309 citations and is from a peer-reviewed journal.
7. (lolli2005cak—cyclindependentactivatingkinase pages 3-4): Graziano Lolli and Louise N. Johnson. Cak—cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle, 4:565-570, Jan 2005. URL: https://doi.org/10.4161/cc.4.4.1607, doi:10.4161/cc.4.4.1607. This article has 309 citations and is from a peer-reviewed journal.
8. (lolli2005cak—cyclindependentactivatingkinase pages 4-5): Graziano Lolli and Louise N. Johnson. Cak—cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle, 4:565-570, Jan 2005. URL: https://doi.org/10.4161/cc.4.4.1607, doi:10.4161/cc.4.4.1607. This article has 309 citations and is from a peer-reviewed journal.
9. (malumbres2011physiologicalrelevanceof pages 4-6): Marcos Malumbres. Physiological relevance of cell cycle kinases. Physiological Reviews, 91:973-1007, Jul 2011. URL: https://doi.org/10.1152/physrev.00025.2010, doi:10.1152/physrev.00025.2010. This article has 300 citations and is from a highest quality peer-reviewed journal.
10. (umeda2005controlofcell pages 2-3): Masaaki Umeda, Akie Shimotohno, and Masatoshi Yamaguchi. Control of cell division and transcription by cyclin-dependent kinase-activating kinases in plants. Plant and Cell Physiology, 46:1437-1442, Sep 2005. URL: https://doi.org/10.1093/pcp/pci170, doi:10.1093/pcp/pci170. This article has 144 citations and is from a domain leading peer-reviewed journal.
11. (łukasik2021cyclindependentkinases(cdk) pages 23-25): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
12. (łukasik2021cyclindependentkinases(cdk) pages 4-5): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
13. (ding2020therolesof pages 21-23): L. Ding, Jiaqi Cao, Wen-Lien Lin, Hongjian Chen, Xianhui Xiong, Hongshun Ao, Min Yu, Jie Lin, and Qing-hua Cui. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. International Journal of Molecular Sciences, 21:1960, Mar 2020. URL: https://doi.org/10.3390/ijms21061960, doi:10.3390/ijms21061960. This article has 610 citations and is from a peer-reviewed journal.
14. (ding2020therolesof pages 5-7): L. Ding, Jiaqi Cao, Wen-Lien Lin, Hongjian Chen, Xianhui Xiong, Hongshun Ao, Min Yu, Jie Lin, and Qing-hua Cui. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. International Journal of Molecular Sciences, 21:1960, Mar 2020. URL: https://doi.org/10.3390/ijms21061960, doi:10.3390/ijms21061960. This article has 610 citations and is from a peer-reviewed journal.
15. (echalier2010recentdevelopmentsin pages 7-8): Aude Echalier, Jane A. Endicott, and Martin E.M. Noble. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1804:511-519, Mar 2010. URL: https://doi.org/10.1016/j.bbapap.2009.10.002, doi:10.1016/j.bbapap.2009.10.002. This article has 162 citations.
16. (echalier2010recentdevelopmentsin pages 8-9): Aude Echalier, Jane A. Endicott, and Martin E.M. Noble. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1804:511-519, Mar 2010. URL: https://doi.org/10.1016/j.bbapap.2009.10.002, doi:10.1016/j.bbapap.2009.10.002. This article has 162 citations.
17. (fisher2019cdk7akinase pages 7-8): Robert P. Fisher. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription, 10:47-56, Dec 2019. URL: https://doi.org/10.1080/21541264.2018.1553483, doi:10.1080/21541264.2018.1553483. This article has 132 citations and is from a peer-reviewed journal.
18. (galbraith2019therapeutictargetingof pages 1-3): Matthew D. Galbraith, Heather Bender, and Joaquín M. Espinosa. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription, 10:118-136, Nov 2019. URL: https://doi.org/10.1080/21541264.2018.1539615, doi:10.1080/21541264.2018.1539615. This article has 96 citations and is from a peer-reviewed journal.
19. (gallorini2012cyclindependentkinasemodulators pages 2-3): Marialucia Gallorini, Amelia Cataldi, and Viviana di Giacomo. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs, 26:377-391, Dec 2012. URL: https://doi.org/10.1007/bf03261895, doi:10.1007/bf03261895. This article has 94 citations and is from a peer-reviewed journal.
20. (harper2001cyclindependentkinases pages 2-4): and J. W. Harper and P. Adams. Cyclin-dependent kinases. Chemical Reviews, 101:2511-2526, Jul 2001. URL: https://doi.org/10.1021/cr0001030, doi:10.1021/cr0001030. This article has 311 citations and is from a highest quality peer-reviewed journal.
21. (liu2000evolutionofcyclindependent pages 1-1): Ji Liu and Edward T. Kipreos. Evolution of cyclin-dependent kinases (cdks) and cdk-activating kinases (caks): differential conservation of caks in yeast and metazoa. Molecular Biology and Evolution, 17:1061-1074, Jul 2000. URL: https://doi.org/10.1093/oxfordjournals.molbev.a026387, doi:10.1093/oxfordjournals.molbev.a026387. This article has 180 citations and is from a highest quality peer-reviewed journal.
22. (liu2000evolutionofcyclindependent pages 1-2): Ji Liu and Edward T. Kipreos. Evolution of cyclin-dependent kinases (cdks) and cdk-activating kinases (caks): differential conservation of caks in yeast and metazoa. Molecular Biology and Evolution, 17:1061-1074, Jul 2000. URL: https://doi.org/10.1093/oxfordjournals.molbev.a026387, doi:10.1093/oxfordjournals.molbev.a026387. This article has 180 citations and is from a highest quality peer-reviewed journal.
23. (liu2000evolutionofcyclindependent pages 2-3): Ji Liu and Edward T. Kipreos. Evolution of cyclin-dependent kinases (cdks) and cdk-activating kinases (caks): differential conservation of caks in yeast and metazoa. Molecular Biology and Evolution, 17:1061-1074, Jul 2000. URL: https://doi.org/10.1093/oxfordjournals.molbev.a026387, doi:10.1093/oxfordjournals.molbev.a026387. This article has 180 citations and is from a highest quality peer-reviewed journal.
24. (malumbres2005mammaliancyclindependentkinases pages 3-3): Marcos Malumbres and Mariano Barbacid. Mammalian cyclin-dependent kinases. Trends in Biochemical Sciences, 30:630-641, Nov 2005. URL: https://doi.org/10.1016/j.tibs.2005.09.005, doi:10.1016/j.tibs.2005.09.005. This article has 1758 citations and is from a domain leading peer-reviewed journal.
25. (malumbres2005mammaliancyclindependentkinases pages 6-7): Marcos Malumbres and Mariano Barbacid. Mammalian cyclin-dependent kinases. Trends in Biochemical Sciences, 30:630-641, Nov 2005. URL: https://doi.org/10.1016/j.tibs.2005.09.005, doi:10.1016/j.tibs.2005.09.005. This article has 1758 citations and is from a domain leading peer-reviewed journal.
26. (malumbres2014cyclindependentkinases pages 1-2): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
27. (malumbres2014cyclindependentkinases pages 2-3): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
28. (malumbres2014cyclindependentkinases pages 5-6): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
29. (malumbres2014cyclindependentkinases pages 6-7): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
30. (schmitz2016cyclindependentkinasesas pages 1-2): M. Lienhard Schmitz and Michael Kracht. Cyclin-dependent kinases as coregulators of inflammatory gene expression. Trends in Pharmacological Sciences, 37:101-113, Feb 2016. URL: https://doi.org/10.1016/j.tips.2015.10.004, doi:10.1016/j.tips.2015.10.004. This article has 98 citations and is from a highest quality peer-reviewed journal.
31. (umeda2005controlofcell pages 1-2): Masaaki Umeda, Akie Shimotohno, and Masatoshi Yamaguchi. Control of cell division and transcription by cyclin-dependent kinase-activating kinases in plants. Plant and Cell Physiology, 46:1437-1442, Sep 2005. URL: https://doi.org/10.1093/pcp/pci170, doi:10.1093/pcp/pci170. This article has 144 citations and is from a domain leading peer-reviewed journal.
32. (wohlbold2006thecyclindependentkinase pages 7-8): Lara Wohlbold, Stephane Larochelle, Jack C.-F. Liao, Geulah Livshits, Juliet Singer, Kevan M. Shokat, and Robert P. Fisher. The cyclin-dependent kinase (cdk) family member pnqalre/ccrk supports cell proliferation but has no intrinsic cdk-activating kinase (cak) activity. Cell Cycle, 5:546-554, Mar 2006. URL: https://doi.org/10.4161/cc.5.5.2541, doi:10.4161/cc.5.5.2541. This article has 83 citations and is from a peer-reviewed journal.
33. (wohlbold2006thecyclindependentkinase pages 9-9): Lara Wohlbold, Stephane Larochelle, Jack C.-F. Liao, Geulah Livshits, Juliet Singer, Kevan M. Shokat, and Robert P. Fisher. The cyclin-dependent kinase (cdk) family member pnqalre/ccrk supports cell proliferation but has no intrinsic cdk-activating kinase (cak) activity. Cell Cycle, 5:546-554, Mar 2006. URL: https://doi.org/10.4161/cc.5.5.2541, doi:10.4161/cc.5.5.2541. This article has 83 citations and is from a peer-reviewed journal.
34. (echalier2010recentdevelopmentsin pages 1-2): Aude Echalier, Jane A. Endicott, and Martin E.M. Noble. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1804:511-519, Mar 2010. URL: https://doi.org/10.1016/j.bbapap.2009.10.002, doi:10.1016/j.bbapap.2009.10.002. This article has 162 citations.
35. (errico2010identificationofsubstrates pages 1-3): Alessia Errico, Krupa Deshmukh, Yoshimi Tanaka, Andrei Pozniakovsky, and Tim Hunt. Identification of substrates for cyclin dependent kinases. Advances in Enzyme Regulation, 50:375-399, Jan 2010. URL: https://doi.org/10.1016/j.advenzreg.2009.12.001, doi:10.1016/j.advenzreg.2009.12.001. This article has 167 citations.
36. (suryadinata2010controlofcell pages 9-10): Randy Suryadinata, Martin Sadowski, and Boris Sarcevic. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (cdk) substrates. Bioscience reports, 30 4:243-55, Aug 2010. URL: https://doi.org/10.1042/bsr20090171, doi:10.1042/bsr20090171. This article has 227 citations and is from a peer-reviewed journal.
37. (zheng2022cyclindependentkinasesand pages 10-12): Zhi-Liang Zheng. Cyclin-dependent kinases and ctd phosphatases in cell cycle transcriptional control: conservation across eukaryotic kingdoms and uniqueness to plants. Cells, 11:279, Jan 2022. URL: https://doi.org/10.3390/cells11020279, doi:10.3390/cells11020279. This article has 28 citations and is from a peer-reviewed journal.
38. (zheng2022cyclindependentkinasesand pages 8-9): Zhi-Liang Zheng. Cyclin-dependent kinases and ctd phosphatases in cell cycle transcriptional control: conservation across eukaryotic kingdoms and uniqueness to plants. Cells, 11:279, Jan 2022. URL: https://doi.org/10.3390/cells11020279, doi:10.3390/cells11020279. This article has 28 citations and is from a peer-reviewed journal.
39. (łukasik2021cyclindependentkinases(cdk) pages 1-2): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
40. (łukasik2021cyclindependentkinases(cdk) pages 2-4): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
41. (łukasik2021cyclindependentkinases(cdk) pages 21-22): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.